PriceTargets.com logo

NASDAQ:ABIO - ARCA biopharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.48 As of 01/25/2021 01:00 AM ET
▼ -0.18 (-3.86%)
1 month | 3 months | 12 months
Get New ARCA biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABIO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ARCA biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.48.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in ARCA biopharma. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2019Ascendiant Capital MarketsSet Price TargetBuy$17.00Medium
i
Rating by Ed Woo at Ascendiant Capital Markets
2/27/2018Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$2.00High
i
2/23/2016Royal Bank of CanadaReiterated RatingSector Perform$5.00 ➝ $4.00N/A
i
2/23/2016CowenReiterated RatingMarket Perform$5.50 ➝ $4.00N/A
i
(Data available from 1/26/2016 forward)
ARCA biopharma logo
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: $4.48
$4.41
$4.73

50 Day Range

MA: $4.28
$4.00
$4.75

52 Week Range

Now: $4.48
$2.21
$22.00

Volume

805,389 shs

Average Volume

598,402 shs

Market Capitalization

$41.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.81

Frequently Asked Questions

What sell-side analysts currently cover shares of ARCA biopharma?

The following equities research analysts have issued stock ratings on ARCA biopharma in the last year:

What is the current price target for ARCA biopharma?

0 Wall Street analysts have set twelve-month price targets for ARCA biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ARCA biopharma in the next year.

What is the current consensus analyst rating for ARCA biopharma?

ARCA biopharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."

What other companies compete with ARCA biopharma?

Other companies that are similar to ARCA biopharma include Trinity Biotech, Biomerica, Navidea Biopharmaceuticals, StageZero Life Sciences, ImmuCell, Achieve Life Sciences, StageZero Life Sciences, Akers Biosciences, BG Medicine, Response Genetics, FluoroPharma Medical, Fuse Science and Hemagen Diagnostics.

How do I contact ARCA biopharma's investor relations team?

ARCA biopharma's physical mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company's listed phone number is 720-940-2200 and its investor relations email address is [email protected] The official website for ARCA biopharma is arcabio.com.